


In the Claims

This listing of claims will replace all prior versions and listings of claims in the patent application.

- 1-3. (Canceled).
4. (Previously Presented) A compound of formula I_{C1}



wherein

A represents cyano;

B represents hydrogen;;

R¹, R², R³ and R⁴ independently represent hydrogen, alkyl, halogen, nitro, cyano or formyl; and
R⁵ and R⁶ independently represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, heteroaryl, heteroaryl-alkyl, alkenyl, carboxyalkyl, cyanoalkyl, diphenylalkyl, aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxy-aryl, or R⁵ and R⁶, together with the nitrogen atom to which they are attached, form a heterocyclic ring system;

or a salt of the compound of formula I_{C1};

with the proviso that the compound is not:

- {3-[(E)-2-cyano-2-(4-fluorophenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- [3-[(E)-2-cyano-2-m-tolylcarbamoyl-vinyl]-indol-1-yl]-acetic acid;
- {3-[(E)-2-(3-bromophenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- [3-[(E)-2-cyano-2-phenylcarbamoyl-vinyl]-indol-1-yl]-acetic acid;
- [3-[(E)-2-benzylcarbamoyl-2-cyano-vinyl]-indol-1-yl]-acetic acid;
- [3-[(E)-2-cyano-2-o-tolylcarbamoyl-vinyl]-indol-1-yl]-acetic acid;
- [3-[(E)-2-cyano-2-p-tolylcarbamoyl-vinyl]-indol-1-yl]-acetic acid;

- {3-[(E)-2-(4-bromo-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-2-(4-ethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-2-(4-methoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-2-(4-ethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-2-isopropylcarbamoyl-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-2-(3-ethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-3-[[2-(1H-indol-3-yl)ethyl]amino]-3-oxo-1-propenyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-2-(4-chloro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-3-(4-methyl-piperidin-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-(3-chloro-4-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-2-(3-phenyl-propylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-2-(2,3-dichloro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-(5-chloro-2-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-2-(4-methoxy-benzylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
 - {3-[(E)-2-cyano-2-(2-fluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid; ~~or and~~
 - {3-[(E)-2-cyano-3-oxo-3-(4-phenyl-piperazin-1-yl)-propenyl]-indol-1-yl}-acetic acid.
5. (Canceled).
6. (Previously Presented) The compound according to claim 4, wherein the groups R⁵ and R⁶ do not form a heterocyclic ring system together with the nitrogen atom to which they are attached; or a salt of the compound.
7. (Previously Presented) The compound according to claim 6, wherein R⁵ is aryl and R⁶ is alkyl, cycloalkyl, alkenyl, cyanoalkyl, diphenylalkyl, heteroaryl-alkyl, aryl-alkyl or aryl; or a salt of the compound.
8. (Previously Presented) The compound according to claim 6, wherein R⁵ is aryl-alkyl and R⁶ is alkyl, aryl or aryl-alkyl; or a salt of the compound.
9. (Previously Presented) The compound according to claim 4, wherein the groups R⁵ and R⁶ form a heterocyclic ring system together with the nitrogen atom to which they are attached; or a salt of the compound.
10. (Previously Presented) The compound according to claim 4, wherein the compound is:
- {3-[(E)-2-cyano-2-(cyclohexylmethyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
 - [3-[(E)-2-cyano-2-phenethylcarbamoyl-vinyl]-indol-1-yl]-acetic acid;
 - [3-[(E)-2-cyano-2-propylcarbamoyl-vinyl]-indol-1-yl]-acetic acid;
 - [3-[(E)-2-cyano-2-cyclohexylcarbamoyl-vinyl]-indol-1-yl]-acetic acid;

- {3-[(E)-2-cyano-2-(3-methyl-butylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-cyano-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-phenoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(naphthalen-2-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-isopropyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-isopropyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-methoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-fluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9H-fluoren-2-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-propyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(biphenyl-4-ylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3,2'-dimethyl-biphenyl-4-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-tert-butyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-benzyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-butyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-acetyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(indan-5-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-Sec-butyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-propyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-phenoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-ethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-ethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-benzyloxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-iodo-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-iodo-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[(4-methoxy-phenyl)-methyl-carbamoyl]-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(methyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(3,4-dihydro-2H-quinolin-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(methyl-p-tolyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[(2,4-dichloro-phenoxy)-phenylcarbamoyl]-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2,5-dimethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;


- {3-[(E)-2-cyano-2-(9-ethyl-9H-carbazol-3-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3,5-bis-trifluoromethyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(5-methoxy-2-methyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-benzoyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-benzyloxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-nitro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-oxo-9H-fluoren-2-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-methoxy-biphenyl-3-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-methoxy-dibenzofuran-3-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-oxo-9H-fluoren-4-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-oxo-9H-fluoren-1-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-benzoyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-chloro-4-methoxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(5-chloro-2-methoxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- 3-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-4-methyl-benzoic acid methyl ester;
- 2-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-benzoic acid methyl ester;
- {3-[(E)-2-cyano-2-(4-trifluoromethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3,5-dimethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-bromo-4-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-bromo-3-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- 4-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-benzoic acid ethyl ester;
- 3-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-benzoic acid methyl ester;
- {3-[(E)-2-cyano-2-(4-trifluoromethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3,5-dimethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-bromo-3-chloro-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-bromo-2-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-acetyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-bromo-4-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzo[1,3]dioxol-5-ylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(phenethyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;

- [3-((E)-2-cyano-2-diphenylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-3-dibenzo[b,f]azepin-5-yl-3-oxo-propenyl)-indol-1-yl]-acetic acid;
- {3-[(E)-2-[(4-chloro-phenyl)-methyl-carbamoyl]-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(6,11-dihydro-dibenzo[b,e]azepin-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-2-diphenethylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[methyl-((R)-1-phenyl-ethyl)-carbamoyl]-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-methyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-[(4-acetyl-phenyl)-methyl-carbamoyl]-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-[(4-acetyl-phenyl)-furan-2-ylmethyl-carbamoyl]-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-carboxymethyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- 3-[benzyl-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloyl]-amino]-propionic acid;
- {3-[(E)-2-cyano-3-(2,3-dihydro-indol-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(carboxymethyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[(2-cyano-ethyl)-phenyl-carbamoyl]-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-[(3-chloro-phenyl)-methyl-carbamoyl]-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(allyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(methyl-o-tolyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(ethyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(butyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- [5-bromo-3-((E)-2-(cyano-2-phenylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-5-fluoro-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-5-methyl-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-6-fluoro-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-6-nitro-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-7-methyl-indol-1-yl]-acetic acid;
- {3-[(E)-3-(2-chloro-phenothiazin-10-yl)-2-cyano-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(phenyl-thiophen-3-ylmethyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[(2,2-diphenyl-ethyl)-phenyl-carbamoyl]-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[phenyl-(3-phenyl-propyl)-carbamoyl]-vinyl]-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-2-{2-(4-fluoro-phenyl)-ethyl}-phenyl-carbamoyl)-vinyl]-indol-1-yl]-acetic acid;

- {3-[(E)-2-cyano-3-(11H-10-oxa-5-aza-dibenzo[a,d]cyclohepten-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(isopropyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(3,4-dichloro-phenyl)-methyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[ethyl-(4-trifluoromethoxy-phenyl)-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-(benzhydryl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[methyl-(2-trifluoromethoxy-phenyl)-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(2,4-difluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[methyl-(4-trifluoromethoxy-phenyl)-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(ethyl-naphthalen-1-yl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(2,4-difluoro-phenyl)-methyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(2,4,6-trifluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2,3,4-trifluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(3,4-dihydro-1H-isoquinolin-2-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-oxo-3-(7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl)-propenyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(3-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- [3-((E)-2-cyano-3-dibenzo[b,f]azepin-5-yl-3-oxo-propenyl)-5-fluoro-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-3-(6,11-dihydro-dibenzo[b,e]azepin-5-yl)-3-oxo-propenyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-phenyl-carbamoyl)-2-cyano-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-(butyl-phenyl-carbamoyl)-2-cyano-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[(3-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[(3,4-dichloro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[methyl-(2-trifluoromethyl-phenyl)-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[(2,4-difluoro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(phenyl-thiophen-3-ylmethyl-carbamoyl)-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-oxo-3-(7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl)-propenyl]-5-fluoro-indol-1-yl}-acetic acid;

- {3-[(E)-2-cyano-2-[ethyl-(4-trifluoromethoxy-phenyl)-carbamoyl]-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(3,4-dihydro-1H-isoquinolin-2-yl)-3-oxo-propenyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(phenethyl-phenyl-carbamoyl)-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-3-dibenzo[b,f]azepin-5-yl-3-oxo-propenyl)-6-methyl-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-3-(6,11-dihydro-dibenzo[b,e]azepin-5-yl)-3-oxo-propenyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-3-oxo-propenyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-phenyl-carbamoyl)-2-cyano-vinyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-(butyl-phenyl-carbamoyl)-2-cyano-vinyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-7-methyl-indol-1-yl}-acetic acid; or
- {3-[(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl]-7-methyl-indol-1-yl}-acetic acid; or a salt of the compound.

11. (Previously Presented) The compound according to claim 4, wherein the compound is of formula I_{C2}



wherein

A represents cyano;

B represents hydrogen;

R¹, R², R³ and R⁴ independently represent hydrogen, alkyl, halogen, nitro, cyano or formyl; and R⁵ and R⁶ independently represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, heteroaryl, heteroaryl-alkyl, alkenyl, carboxyalkyl, cyanoalkyl, diphenylalkyl, aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxy-aryl, or R⁵ and R⁶, together with the nitrogen atom to which they are attached, form a heterocyclic ring system;

provided that at least one of the following conditions must be met:

- ❖ one of R¹, R², R³ and R⁴ is different from a hydrogen atom; or
- ❖ when R⁵ and R⁶ are such that they do not form a heterocyclic ring system together with the nitrogen atom to which they are attached, then both R⁵ and - R⁶ are different from hydrogen and one of R⁵ and R⁶ is different from alkyl; or

when R⁵ and R⁶ are such that they form a heterocyclic ring system together with the nitrogen atom to which they are attached, then said heterocyclic ring system is neither an unsubstituted or substituted piperidine nor an unsubstituted or substituted piperazine; or a salt of the compound.

12. (Previously Presented) A pharmaceutical composition comprising at least one compound according to claim 4 and a pharmaceutically acceptable carrier.

13. (Canceled).

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (Canceled).

18. (Currently Amended) ~~The A method for preventing or treating chronic or acute allergic immune disorder of claim 13 comprising the administration of a therapeutically effective amount of the compound according to claim 4,~~ wherein the disorder ~~comprises~~ is allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, ~~systemic mast cell disorders,~~ anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia- reperfusion injury, ~~cerebrovascular disorders,~~ pleuritis, ulcerative colitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, or basophilic leukocytosis.

19. (Previously Presented) The compound of claim 4, wherein the compound is {3-[(E)-2-cyano-3-(3,4-dihydro-2H-quinolin-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid.

20. (Previously Presented) The compound of claim 4, wherein:

- ❖ A is cyano;
- ❖ B is hydrogen;

- ❖ R^1 , R^2 , R^3 and R^4 are all hydrogen atoms or one of R^1 , R^2 , R^3 and R^4 is halogen while the others are all hydrogen; and
 - ❖ at least one of R^5 and R^6 is chosen from the group consisting of heteroaryl, heteroaryl-alkyl, diphenylalkyl, aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl and aryloxy-aryl; or R^5 and R^6 , together with the nitrogen atom to which they are attached, form a heterocyclic ring system; or a salt of the compound.
21. (Canceled).
22. (Currently Amended) ~~The Δ method for preventing or treating~~ [[a]] chronic or acute allergic immune disorder of claim 21 disorders comprising the administration of a therapeutically effective amount of the compound according to claim 20, wherein the disorder ~~comprises~~ is allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, ~~systemic mast cell disorders,~~ anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia- reperfusion injury, ~~cerebrovascular disorders,~~ pleuritis, ulcerative colitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, or basophilic leukocytosis.
23. (Canceled).
24. (Currently Amended) ~~The Δ method for preventing or treating~~ [[a]] chronic or acute allergic immune disorder of claim 23 disorders comprising the administration of a therapeutically effective amount of the compound according to claim 10, wherein the disorder ~~comprises~~ is allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, ~~systemic mast cell disorders,~~ anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia- reperfusion injury, ~~cerebrovascular disorders,~~ pleuritis, ulcerative colitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, or basophilic leukocytosis.